1 / 34

Understanding Treatment of Chronic Hepatitis C: Telaprevir and Boceprevir

Explore the implications of data in monoinfection versus co-infection, SVR rates with telaprevir and boceprevir, futility rules in treatment-experienced patients, adverse events management, anemia strategies, and more. Learn practical insights on managing adverse effects and improving SVR rates with RBV dose adjustments.

destiny-espinoza
Télécharger la présentation

Understanding Treatment of Chronic Hepatitis C: Telaprevir and Boceprevir

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. What do data in monoinfection mean in relation to co-infection?

  2. Treatment of Chronic Hepatitis C

  3. Telaprevir and Boceprevir SVR by patient Type

  4. SVR Rates With BOC or TVR in GT1 Treatment-Experienced Patients

  5. Futility Rules for BOC or TVR + PegIFN/RBV

  6. Telaprevir + PR: Adverse Events

  7. Boceprevir + PR: Adverse Events

  8. Practical Strategies: Managing Anemia

  9. Telaprevir: SVR Rates by RBV Dose Reduction in ADVANCE and ILLUMINATE

  10. Boceprevir: SVR in Pts With Hb < 10 g/dL by EPO and/or RBV Dose Reduction

  11. Adverse Effect Management: Anaemia

  12. My patient (SS)

  13. Accepted for Boceprevir EAP

  14. Viral Response and Tolerability

  15. Viral Response and Tolerability

  16. King’s cohort n=20: adverse effects

  17. New HCV agents : What are the possible challenges?

More Related